Show Filters

Searches all publications.

Search Fulltext



Select publication to see the relevant sections.

Publication Date

    E.g., 2018-06-24
    E.g., 2018-06-24


19310 items
3:50 PM, Apr 27, 2018  |  BioCentury | Politics, Policy & Law

New hopes in IPR

The U.S. Supreme Court dashed biopharma’s hopes that the inter partes review system will quickly disappear, and threw a monkey wrench into the U.S. Patent and Trademark Office’s procedures for streamlining the adjudication of IPR...
2:48 PM, Apr 27, 2018  |  BioCentury | Regulation

Independent opportunities

The scenario the U.K. is trying to avoid is a full disconnect from EMA when the Brexit curtain falls. But a clean break from the agency could create opportunities for the U.K.’s Medicines and Healthcare...
1:43 PM, Apr 27, 2018  |  BioCentury | Emerging Company Profile

Cinclus’ acid inhibition

Cinclus Pharma AG is developing a fast-acting potassium-competitive acid blocker designed to last longer than proton pump inhibitors and marketed P-CABs to treat severe erosive gastrointestinal reflux disease. PPIs such as Nexium esomeprazole and Prilosec...
1:32 PM, Apr 27, 2018  |  BioCentury | Finance

Earnings on deck

Earnings on deck At least 14 profitable biotechs and pharmas are slated to report earnings this week. (A) During trading hours in Tel Aviv, before U.S. exchanges open CompanyDatePre/post mkt1Q18 EPS est1Q17 EPSExpected chgAllergan plc (NYSE:AGN)4/30Pre$3.35$3.350%Merck &...
8:05 AM, Apr 27, 2018  |  BioCentury | Finance

Revolution revamp

Revolution Medicines Inc.’s pivot to cancer and preclinical proof-of-concept data for its lead program convinced Nextech Invest to lead the company’s $56 million series B round. Fellow new investors Casdin Capital and Schroder Adveq and existing...
5:04 AM, Apr 25, 2018  |  BioCentury | Finance

Rare disease rally

While 5AM Ventures has typically backed platform plays in the rare disease space, the firm is looking to newco Rallybio LLC to build a portfolio out of one-off rare disease candidates sourced from academia and...
4:12 AM, Apr 24, 2018  |  BioCentury | Finance

Protein player

By modulating targets upstream of the ubiquitin proteasome system and inducing both stabilization and destabilization of target proteins, Third Rock Ventures believes newco Cedilla Therapeutics Inc. could have a broader reach than competing protein degradation...
6:28 PM, Apr 20, 2018  |  BioCentury | Product Development

Redrawing the lines

Word that Merck & Co. Inc.’s Keytruda pembrolizumab had “won” the first-line lung cancer showdown with Bristol-Myers Squibb Co. at AACR spread quickly on Monday, but there was little discussion among investors and in the...
5:44 PM, Apr 20, 2018  |  BioCentury | Finance

Takeda’s math problem

A hefty net debt load of $18.8 billion for Shire plc (LSE:SHP; NASDAQ:SHPG) means Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) is having to pick its poison to reach a deal. The Japanese pharma is grappling with giving...
5:16 PM, Apr 20, 2018  |  BioCentury | Finance

Qiming’s cross-border connection

Qiming Venture Partners chose to focus its first ex-China fund on healthcare because the firm sees more interest in cross-border collaborations in life sciences than some of the other industries it invests in. Qiming unveiled...